News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Future Directions for Precision Medicine in Advanced NSCLC

EP. 1: Advances in Frontline Therapy for EGFR+ NSCLC

October 23rd 2018

EP. 2: Resistance Mechanisms and Sequencing for EGFR+ NSCLC

October 23rd 2018

EP. 3: Promising EGFR Inhibitors in Development for NSCLC

October 23rd 2018

EP. 4: Frontline Chemo and TKI Combination in EGFR+ NSCLC

October 23rd 2018

EP. 5: Adjuvant TKI for Early Stage EGFR+ NSCLC

October 23rd 2018

EP. 6: Updates in the Treatment of ALK+ and ROS1+ NSCLC

October 23rd 2018

EP. 7: Practice-Changing Frontline Treatment of ALK+ NSCLC

October 23rd 2018

EP. 8: Second Generation ALK Inhibitors in NSCLC

October 23rd 2018

EP. 9: Additional Targets in NSCLC: BRAF V600E and BRAF Variants

October 23rd 2018

EP. 10: NTRK Gene Fusions: Rare Yet Actionable

October 23rd 2018

EP. 11: Targeting HER2 Mutations in NSCLC: What Do We Know?

October 23rd 2018

EP. 12: Response Rates in Treatment of MET-Amplified NSCLC

October 23rd 2018

EP. 13: Advances in RET Inhibition in NSCLC

October 23rd 2018

EP. 14: Mutation Testing for All Patients With NSCLC

October 23rd 2018

Trending on OncLive

Bexobrutideg Could Pave the Way for BTK Degraders in R/R Chronic Lymphocytic Leukemia

Domvanalimab/Zimberelimab Plus Chemotherapy Fails to Improve OS in HER2-Negative Gastroesophageal Adenocarcinoma

Extended FOLFOX, Atezolizumab Duration Linked With Improved DFS in Stage III dMMR Colon Cancer

Dr Shah on the Significance of DAYBreak CLL-201 and Bexobrutideg for the CLL Treatment Paradigm

Dr Bekaii-Saab on the FDA Approval of Zenocutuzumab in NRG1+ Cholangiocarcinoma